A major obstacle to curing chronic myeloid leukaemia (CML) is residual disease maintained by tyrosine kinase inhibitor (TKI)-persistent leukemic stem cells (LSCs).
SIGNIFICANCE
In CML, TKI-persistent LSCs remain an obstacle to cure and approaches to eradicate them remain a significant unmet clinical need. We demonstrate that EZH2
and H3K27me3 reprogramming is important for LSC survival, but renders them sensitive to the combined effects of EZH2i and TKI. This represents a novel approach to more effectively target LSCs in patients receiving TKI treatment.
INTRODUCTION
Chronic myeloid leukemia (CML) is a clonal HSC disorder, arising through the acquisition and expression of the fusion BCR-ABL1 tyrosine kinase which stimulates a number of key survival pathways to drive the disease. Despite the introduction of TKIs which have transformed the clinical course of CML from a fatal to a manageable disease for the vast majority of patients, only ~10% of those who present in chronic phase can discontinue treatment and maintain a therapy-free remission without relapse (5) . The remaining 90% of patients require life-long TKIs and can experience serious side effects, compliance issues and high costs, or they develop TKI-resistance (20-30% of cases), and/or progress to advanced disease for which there are no effective drug therapies. The low cure rate in CML is thought to be due to a pool of TKI-persistent and BCR-ABL1 kinase-independent (1) LSCs.
LSCs in CML are defined as Philadelphia chromosome-positive (Ph + ) CD34 + CD38
primitive progenitor cells that show a higher capacity to engraft in immunocompromised mice than bulk CD34 + cells (6) , have stem cell properties (quiescence and self-renewal), are prone to genomic instability (7) and resistant to apoptosis (3, 4) . Novel therapeutic strategies that target these LSCs must be developed to address an important unmet clinical need for the vast majority of patients currently on TKI therapy.
The epigenetic "writer" complex PRC2 is fundamental for defining stem cell identity where it primarily regulates gene repression using H3K27me3 (8) . Whilst its methyltransferase activity can be mediated by either EZH1 or EZH2; aberrant H3K27me3 and EZH2 activity has been implicated in the progression or poor prognosis of solid tumors and hematological malignancies (9, 10) . However, little is known about the role of EZH2 in CML and unlike other myeloid malignancies, inactivating mutations of EZH2 in CML are rare, (11, 12) although up-regulation of EZH2 can result in a form of myeloproliferative disease (13) . Fig. S1a-c) . Significant down-regulation of EZH1 in LSCs was found often in combination with EZH2 up-regulation, creating a scenario where the relative levels of EZH2 compared to EZH1 increased 2-16 fold across the ten CML samples we examined (Fig. 1a) . Levels of EZH2, as well as other PRC2
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components, were significantly down-regulated in LSCs treated with TKI in vitro, indicative of kinase dependent regulation. The levels of EZH1, however, appeared kinase independent, thus maintaining an EZH balance favouring EZH2 in TKIpersistent cells ( Supplementary Fig. S2a-c) .
To understand the molecular consequences of PRC2 mis-regulation, we performed
ChIP-sequencing in normal and CML primary stem and progenitor cell samples (a first in CML LSCs). We identified statistically significant changes in H3K27me3 levels at promoters in three pairwise comparisons ( Fig. 1b; Supplementary Fig. S3a ). In total, across the three CML samples, changes in H3K27me3 levels were identified at 4101 promoters, 83% of which were unique to CML (Fig. 1c) . A quarter of these were common to all three samples and consistent with gains or losses of EZH2 target genes (Supplementary Fig. S3b) . A significant majority of these changes (2978; 73%) occurred between the HSC and LSC, indicative of extensive epigenetic reprogramming in the LSC.
Whilst the repressive function of EZH2 and H3K27me3 is well documented, changes in gene expression at EZH2 target genes are not always mechanistically linked to H3K27me3 levels in normal hematopoiesis (14) . We therefore asked what impact H3K27me3 reprogramming would have on gene expression in CML. Significant mRNA expression changes between normal and leukemic stem and progenitor cells were determined globally (Supplementary Fig. S4a ; Supplementary Table S1 ) and from these we identified a subset of H3K27me3 reprogrammed target genes, whose mRNAs were either up-or down-regulated (examples shown, Fig. 1d ). In agreement with previous observations (14), we found no evidence that H3K27me3 levels were linked to changes in gene expression during normal cell fate decisions (HSC → P a g e | 5
HPC) (Fig. 1e) . However, in the three CML samples, the association between changes in gene expression and H3K27me3 levels was significantly different from that predicted by H3K27me3 reprogramming ( Fig. 1e; Supplementary Fig. S4b) and indicative of H3K27me3 having its canonical repressive role. This association was most significant in the "early" changes (HSC vs LSC), particularly amongst promoters reprogrammed in all 3 CML samples (common; Fig. 1f ; Supplementary   Fig. S4c) , and pointed to an altered dependency between H3K27me3 and gene expression primarily in the LSC (Fig. 1g) .
Based on the epigenetic evidence, we hypothesized that EZH2 inhibition would represent a potential novel therapeutic strategy to selectively target LSCs given that
HSCs require EZH1 (14) for survival but not EZH2 (15) . We therefore treated CML and normal primary cells in vitro with a highly specific EZH2i, GSK343 (16) ( 3a) . However, we found little evidence that TKI or EZH2i returned mRNA levels of Furthermore, combination treatment with DAS and EZH2i led to a significant reduction in cell viability, even in the undivided 'TKI-persistent' cells ( Fig. 3c) , and was accompanied by increased apoptosis (Fig. 3d ) and a pronounced reduction in CFC and CFC/GEMM outputs compared to DAS treatment alone (Fig. 3e) .
Furthermore, combined EZH2i and DAS treatments reduced LTC-IC outputs to 1%
of those of no drug controls ( Supplementary Fig. S5e ) and the effects of EZH2i in the presence of DAS were more than additive (Fig. 3f) . DAS treatment similarly reduced cell viability and the CFC potential of cells in which EZH2 was knocked down by shRNAs (Fig. 3g) .
To As TKI-persistent cells are refractory to apoptosis (3, 4), we examined the mechanism of action of combined DAS plus EZH2i on the mRNA expression of a set of genes, including 14 H3K27me3 targets from apoptotic pathways (Fig. 4a) . BCL6, an H3K27me3 target and a known repressor of p53 and CDKN2A (p16/ARF) in TKIpersistent cells (21, 22) was up-regulated by combined DAS plus EZH2i treatment.
Nonetheless, there was a significant up-regulation of apoptotic genes, including p53 transcriptional targets (e.g. CDKN1A, BAX, PUMA, NOXA, TNFRS10B), and an enhanced activation of H3K27me3 targets, including CDKN2A, compared to DAS or EZH2i treatments alone. In keeping with our phenotypic data, the enhanced activation of H3K27me3 targets and apoptotic genes exceeded predicted levels based on additive effects (Fig. 4b) . Furthermore, we confirmed increased levels of the p53 protein in CML CD34 + cells treated with EZH2i and in combination with DAS ( Fig. 4c) . We generated a connectivity map between targets of EZH2 (H3K27me3), BCL6 and p53 in the apoptosis pathway ( Fig. 4d ) and propose that EZH2 inhibition, when potentiated by TKI, could engage apoptosis downstream of p53 through reactivation of pro-apoptotic targets (e.g. PUMA, BIM), and/or by directly rescuing p53-mediated apoptosis by overcoming BCL6-and EZH2-mediated repression upstream of p53. promoters where all three samples gave read densities greater than 0 at a given promoter were used for further data mining. As a result, read densities for 26,760 promoters (H3K27me3) or 24,292 promoters (H3K27me1) were used for the analyses described in the text.
Bona fide H3K27me3 target genes were defined as follows. k-means clustering of
ChIP-sequencing read densities/10 6 reads at a resolution of 50 bp across 5 kb at each each of 33,626 promoters (2.5 kb bp up-and down-stream of the TSS) was performed by seqMINER (26) . Clusters were generated that defined promoters having (i) H3K4me3 only, (ii) both H3K4me3 and H3K27me3, or (iii) neither histone modification ( Supplementary Fig. S16a,b) . Membership of gene promoters in these three classifications was validated by ChIP qPCR (Supplementary Fig. S17a-c) using SYBR-Green Master (Rox) (Roche) in a Stratagene Mx3000P qPCR system (Agilent Technologies). Oligonucleotide primer pairs available upon request.
Promoters defined as "H3K4me3 only" or having "neither" histone modification were then used as a measure of background noise for H3K27me3 in ChIP-sequencing datasets derived from each patient or normal sample. On a per sample basis, those promoters with H3K27me3 read densities (across 2 kb promoter windows) that were 3 standard deviations above background noise were considered as H3K27me3 targets. In this way, each H3K27me3 ChIP-sequencing dataset had a uniquely defined measure of background (i.e., a threshold) above which bona fide H3K27me3 targets could be identified.
Statistically significant changes in H3K27me3 read densities at promoters of H3K27me3 target genes (defined as above) were determined using either Student ttests or one-sample t-tests as appropriate. Significance was determined at the level of individual promoters. In addition, promoters shown to be statistically significant were also required to have at least 1.5 fold changes in H3K27me3 levels to be considered as promoters with obvious changes. Promoters ranked as having H3K27me1 levels in the top 25% of all promoters genome-wide were used for the analysis described in Supplementary Fig. S8a,b . Yates Chi-square or Fischer Exact tests were used to determine statistically significant differences between observed vs 
